STOCK TITAN

Axim Biotechnologies Inc - AXIM STOCK NEWS

Welcome to our dedicated news page for Axim Biotechnologies (Ticker: AXIM), a resource for investors and traders seeking the latest updates and insights on Axim Biotechnologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Axim Biotechnologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Axim Biotechnologies's position in the market.

Rhea-AI Summary
AXIM Biotechnologies, Inc. CEO John Huemoeller II discusses the company's FDA-cleared diagnostic assays for dry eye disease and allergies in a fireside chat interview. The company is focused on providing quantitative diagnostic solutions using teardrops, with tests for Lactoferrin and IgE. The interview sheds light on AXIM's research in Parkinson's diagnostic program and its impact on treatment efficacy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
none
-
Rhea-AI Summary
AXIM Biotechnologies' commercialization partner, Verséa Ophthalmic, places a re-stock order for AXIM's digital assay reader, indicating a growing clinical presence and revenue opportunity. The order reflects successful clinical validation and an impending expansion of AXIM's diagnostic program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.75%
Tags
none
-
Rhea-AI Summary
AXIM Biotechnologies, Inc. (OTCQB: AXIM) has signed a contract manufacturing agreement with Auer Precision to scale production of its FDA-cleared diagnostic assays for Dry Eye Disease. The partnership aims to meet the growing demand for the tests in a cost-effective way, enabling AXIM to focus on research and development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
Rhea-AI Summary
AXIM develops rapid diagnostic assay for Parkinson's Disease biomarker
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.33%
Tags
none
-
Rhea-AI Summary
AXIM Biotechnologies, Inc. (OTCQB: AXIM) announces the expansion of its IP portfolio with 13 filings and allowances, covering a wide range of diagnostic solutions including SARS-Cov-2, Lactoferrin, IgE, Lacritin, MMP-9, and cancer biomarkers. The USPTO has granted patents for COVID-19 neutralizing antibody testing, rapid diagnostics for cancers, and point-of-care cancer detection methods, enhancing the company's value proposition and market potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
none
Axim Biotechnologies Inc

OTC:AXIM

AXIM Rankings

AXIM Stock Data

3.30M
174.57M
33.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
San Diego

About AXIM

axim biotechnologies, inc. is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and sars-cov-2 (covid-19). the company's neucovix is the rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent sars-cov-2 from entering the host cells. it is developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis. the company was formerly known as axim international inc. and changed its name to axim biotechnologies, inc. in july 2014. axim biotechnologies, inc. was founded in 2010 and is headquartered in san diego, california.